BRD2 and acute myeloid leukemia: Our results indicated the therapeutic potential of dBET1, a PROTAC inhibitor of BET family members (i.e., BRD2, BRD3, and BRD4) in Kasumi (AML1-ETO), NB4 (PML-RARa), THP-1 (MLL-AF9), and MV4-11 (MLL-AF4) AML cell lines representing four major molecular subtypes of AML.